Frederick Weidman, MD
Ophthalmology · Charlotte, NCNPI 1730179102
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,484 of the $5,057 with a category attached, or 68.9%. It is spread thinly across 19 manufacturers, the largest accounting for just 16.1%.
Across 126 payments — averaging $40.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$814
- Notal Vision, Inc.$792
- AbbVie$723
- Genentech USA, Inc.$566
- Astellas Pharma US Inc$506
- Apellis Pharmaceuticals, Inc.$415
- plus $1K from 13 others
Across 18 payments — averaging $35.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$630
What the payments were for
- Speaking & faculty fees$76015%
- Food & beverage$3,48469%
- Ownership interest$81416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $814 |
| Notal Vision, Inc. | 6 | $792 |
| AbbVie(2 entities) | 24 | $723 |
| Genentech USA, Inc. | 19 | $566 |
| Astellas Pharma US Inc | 12 | $506 |
| Apellis Pharmaceuticals, Inc. | 14 | $415 |
| Alimera Sciences, Inc. | 18 | $325 |
| Regeneron Healthcare Solutions, Inc. | 7 | $238 |
| NEW World Medical,inc. | 1 | $132 |
| ANI Pharmaceuticals, Inc. | 2 | $123 |
| Spark Therapeutics, Inc. | 2 | $106 |
| Genentech, Inc. | 1 | $57 |
| Biogen | 3 | $55 |
| Novartis | 3 | $52 |
| Kala Pharmaceuticals, Inc. | 3 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Alcon | 1 | $39 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$258
- VABYSMO$240
- Syfovre$240
- OZURDEX$222
- ForeseeHome$181
- Kahook Dual Blade$132
- Clearpath$132
- Ahmed Glaucoma Valve$132
- Streamline$132
- EYLEA HD$118
How this compares
$5,057 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $17,734 |
| Prednisolone Acetate | 341 | $16,170 |
| ProlensaBromfenac Sodium | 31 | $10,210 |
| Ketorolac Tromethamine | 117 | $3,972 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $3,533 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,523 |
| Loteprednol Etabonate | 14 | $2,342 |
| Dorzolamide Hcl | 71 | $1,135 |
| MoxifloxacinMoxifloxacin Hcl | 30 | $1,092 |
| Brimonidine Tartrate | 59 | $967 |
| Latanoprost | 48 | $499 |
| Timolol Maleate | 73 | $470 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $723 | $17,73413 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $40 | $12,55245 claims |
| AlconSimbrinza | $39 | $2,52313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Charlotte
- Thomas MundorfCharlotte$220K
- Charles BlotnickCharlotte$18K
- Adrian ElfersyCharlotte$13K
- Joseph KrugCharlotte$10K
- Royce SyracuseCharlotte$10K
- William HammondsCharlotte$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.